621 related articles for article (PubMed ID: 19953081)
1. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
Simonelli F; Maguire AM; Testa F; Pierce EA; Mingozzi F; Bennicelli JL; Rossi S; Marshall K; Banfi S; Surace EM; Sun J; Redmond TM; Zhu X; Shindler KS; Ying GS; Ziviello C; Acerra C; Wright JF; McDonnell JW; High KA; Bennett J; Auricchio A
Mol Ther; 2010 Mar; 18(3):643-50. PubMed ID: 19953081
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
[TBL] [Abstract][Full Text] [Related]
5. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
[TBL] [Abstract][Full Text] [Related]
6. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
7. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.
Rakoczy EP; Narfström K
Int J Biochem Cell Biol; 2014 Nov; 56():153-7. PubMed ID: 25286304
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.
Amado D; Mingozzi F; Hui D; Bennicelli JL; Wei Z; Chen Y; Bote E; Grant RL; Golden JA; Narfstrom K; Syed NA; Orlin SE; High KA; Maguire AM; Bennett J
Sci Transl Med; 2010 Mar; 2(21):21ra16. PubMed ID: 20374996
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of gene therapy on Leber's congenital amaurosis.
Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
[TBL] [Abstract][Full Text] [Related]
11. The human visual cortex responds to gene therapy-mediated recovery of retinal function.
Ashtari M; Cyckowski LL; Monroe JF; Marshall KA; Chung DC; Auricchio A; Simonelli F; Leroy BP; Maguire AM; Shindler KS; Bennett J
J Clin Invest; 2011 Jun; 121(6):2160-8. PubMed ID: 21606598
[TBL] [Abstract][Full Text] [Related]
12. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
13. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.
Testa F; Maguire AM; Rossi S; Pierce EA; Melillo P; Marshall K; Banfi S; Surace EM; Sun J; Acerra C; Wright JF; Wellman J; High KA; Auricchio A; Bennett J; Simonelli F
Ophthalmology; 2013 Jun; 120(6):1283-91. PubMed ID: 23474247
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy: light is finally in the tunnel.
Cao H; Molday RS; Hu J
Protein Cell; 2011 Dec; 2(12):973-89. PubMed ID: 22231356
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.
Li X; Li W; Dai X; Kong F; Zheng Q; Zhou X; Lü F; Chang B; Rohrer B; Hauswirth WW; Qu J; Pang JJ
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):7-15. PubMed ID: 21169527
[TBL] [Abstract][Full Text] [Related]
16. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
Cideciyan AV
Prog Retin Eye Res; 2010 Sep; 29(5):398-427. PubMed ID: 20399883
[TBL] [Abstract][Full Text] [Related]
17. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
[TBL] [Abstract][Full Text] [Related]
19. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis.
Ku CA; Chiodo VA; Boye SL; Goldberg AF; Li T; Hauswirth WW; Ramamurthy V
Hum Mol Genet; 2011 Dec; 20(23):4569-81. PubMed ID: 21880665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
